Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools announced participation in several investor conferences in June 2024. The schedule includes:
- Jefferies Global Healthcare Conference on June 5th & 6th, where CEO Michael Egholm will join a fireside chat on June 5th at 2:30 p.m. ET.
- Scotiabank Healthcare 1x1 Day on June 20th, featuring 1x1 investor meetings in Toronto, Canada.
- TD Cowen’s 3rd Annual Tool/Dx Revolution Conference from June 24th to 26th, with CEO Michael Egholm participating in a panel discussion on M&A consolidation on June 25th at 11:50 a.m. PT.
Presentations will be webcast live on the company's Investor Relations page.
- Participation in high-profile investor conferences may increase visibility within the investment community.
- CEO Michael Egholm's involvement in discussions and fireside chats can enhance investor confidence.
- Webcasting the presentations allows for broader accessibility and engagement from stakeholders.
- No new financial or clinical data announcements were made, which may not meet investor expectations.
- Potential investor fatigue due to multiple conferences in a short period.
- Lack of specific details on strategic initiatives or business developments.
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that its management team will participate in the following investor conferences in the month of June:
- Jefferies Global Healthcare Conference on June 5th & 6th 2024. President and CEO, Michael Egholm, PhD, will participate in a fireside chat on Wednesday June 5th at 2:30 p.m. ET
- Scotiabank Healthcare 1x1 Day on June 20th 2024. Management will participate in 1x1 investor meetings in Toronto, Canada
- TD Cowen’s 3rd Annual Tool/Dx Revolution Conference, June 24th - 26th 2024. President and CEO, Michael Egholm, PhD, will participate in a Panel Discussion: Deal or No Deal – M&A Consolidation and Combination as a Path to Growth on Tuesday, June 25th at 11:50 a.m. PT
Available presentations will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: www.standardbio.com/legal/salesterms. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact:
David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com
FAQ
What conferences will Standard BioTools attend in June 2024?
When is Michael Egholm's fireside chat at the Jefferies Global Healthcare Conference?
What will be discussed in the panel at TD Cowen's Tool/Dx Revolution Conference?
How can investors access the presentations from Standard BioTools' conferences?
